

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 16, 2015

Xenetic Biosciences, Inc.  
(Exact name of registrant as specified in its charter)

Nevada  
(State or other jurisdiction of incorporation)

333-178082  
(Commission File Number)

45-2952962  
(I.R.S. Employer Identification No.)

99 Hayden Avenue, Suite 230  
Lexington MA 02421  
(Address of principal executive offices)

Registrant's telephone number, including area code: 781-778-7722

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

## **SECTION 5 – Corporate Governance and Management**

### **Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers**

Effective April 16, 2015, Mark Leuchtenberger resigned from of our board of directors because of a potential for conflict between his new role as CEO of Chiasma and that company's similarly planned IPO directed financing. There was no known disagreement with Mr. Leuchtenberger on any matter relating to the Company's operations, policies or practices.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### **Xenetic Biosciences, Inc.**

/s/ M. Scott Maguire

M. Scott Maguire

Chief Executive Officer

Date: April 20, 2014

